Medifast, Inc.
NYSE:MEDPersonal Products & Services
-$0.01 today
- Market cap
- $136.43M
- Beta
- 0.66
- P/E (TTM)
- -6.2
- EPS (TTM)
- -$1.82
Volume 0.09M
Average 0.21M
MED Net Income
Bottom-line profit after all expenses, interest, and taxes.
Medifast, Inc.NYSE: MED
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$2.12M, compared with -$772K a year earlier. Trailing-twelve-month net income was -$20.02M.
Context
- Net income amounted to 4.8% of revenue in FY2025, up 4.5 pp from a year earlier.
- Net income increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of -$9.44M (+49.4%) for the fiscal year ending Dec 2026, a step up from the -993.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$2.12M+88.3% QoQ
- Last fiscal yearDec 2025
- -$18.67M-993.0% YoY
- LTMMar 2026
- -$20.02M-186.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -174.9% | -393.1% | -218.2 pp |
| 1 year | -993.0% | +49.4% | +1042.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (18.67M) USD
- Year-over-year change
- -993.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (18.67M) | -993.0% |
| FY2024 | 2024-12-31 | 2.09M | -97.9% |
| FY2023 | 2023-12-31 | 99.42M | -30.8% |
| FY2022 | 2022-12-31 | 143.57M | -12.5% |
| FY2021 | 2021-12-31 | 164.03M | — |
Net Income vs competitors
How MED compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -186.2% is the 8th highest of 10, against a peer median of +3.0%.
- Net income amounts to 5.8% of revenue for MED, versus a peer median of 5.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Dec 2025 | $42.84M USD | +42.9% | +26.5% | 5.6% | |
| LTM Jan 2026 | $11.08M USD | -37.0% | — | 3.9% | |
| LTM Feb 2026 | $5.36M USD | +180.7% | -54.6% | 1.6% | |
| LTM Mar 2026 | -$11.03M USD | +45.2% | — | 12.3% | |
| LTM May 2026 | -$12.56M USD | -224.5% | — | 1.3% | |
| LTM Mar 2026 | -$20.02M USD | -186.2% | — | 5.8% | |
| LTM Mar 2026 | -$30.22M USD | -18.9% | — | 5.0% | |
| LTM Mar 2026 | -$44.61M USD | +43.8% | — | 17.7% | |
| FY2025 | -HK$52.53M HKD | -259.7% | — | 11.4% | |
AIIORobo.ai Inc. | FY2025 | -$167.34M USD | +3.0% | — | 17614.9% |
| Peer median (excluding MED) | — | +3.0% | -14.1% | 5.6% | |
Competitors are the stored peer set for MED. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.53B | 1.6B | 1.07B | 602.46M | 385.79M |
| Cost of Revenue | 398.49M | 458.16M | 296.2M | 157.84M | 110.6M |
| Gross Profit | 1.13B | 1.14B | 775.85M | 444.62M | 275.19M |
| Gross Margin | 73.9% | 71.3% | 72.4% | 73.8% | 71.3% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 911.36M | 955.61M | 649.45M | 441.75M | 289.4M |
| Operating Expenses | 911.36M | 955.61M | 649.45M | 441.75M | 289.4M |
| Depreciation & Amortization | 6.81M | 10.98M | 13.11M | 12.71M | 10.5M |
| EBITDA | 222.94M | 195.74M | 141.9M | 16.49M | 4.86M |
| EBITDA Margin | 14.6% | 12.2% | 13.2% | 2.7% | 1.3% |
| Operating Income | 216.24M | 184.81M | 126.4M | 2.88M | (14.21M) |
| Operating Margin | 14.2% | 11.6% | 11.8% | 0.5% | -3.7% |
| Interest Income | 0 | 0 | 2.49M | 4.8M | 5.52M |
| Interest Expense | 231K | 701K | 0 | 0 | 0 |
| Other Income / Expenses | (112K) | (747K) | 2.4M | 909K | 8.57M |
| Income Before Tax | 216.13M | 184.06M | 128.8M | 3.79M | (5.64M) |
| Pre-Tax Margin | 14.2% | 11.5% | 12.0% | 0.6% | -1.5% |
| Income Tax Expense | 52.1M | 40.49M | 29.38M | 1.7M | 13.03M |
| Net Income | 164.03M | 143.57M | 99.42M | 2.09M | (18.67M) |
| Net Margin | 10.7% | 9.0% | 9.3% | 0.3% | -4.8% |
| EPS (Basic) | 14.01 | 12.82 | 9.10 | 0.19 | (1.70) |
| EPS (Diluted) | 13.89 | 12.73 | 9.10 | 0.19 | (1.70) |
| Weighted Avg Shares | 11.71M | 11.2M | 10.88M | 10.93M | 10.98M |
| Weighted Avg Shares (Diluted) | 11.81M | 11.28M | 10.92M | 10.96M | 10.98M |
Medifast, Inc.
NYSE:MED
Intrinsic Alpha fair value
Locked
Current Price
$12.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.